12:00 AM
 | 
Oct 27, 2008
 |  BioCentury  |  Product Development

Bleeding data

Bleeding data

Company Trial Arm (n) % major bleeding [95% CI]
Bristol-Myers (NYSE:BMY) AFASAK Warfarin (335) Control (336) 0.6% 0.0%
SPAF ...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >